Zulresso
Zulresso is the brand name for brexanolone, a neuroactive steroid approved for the treatment of postpartum depression (PPD) in adult women. It was developed by Sage Therapeutics and is delivered as a continuous intravenous infusion. Zulresso is notable for being the first medication specifically indicated for PPD.
Brexanolone is a formulation of allopregnanolone, an endogenous neurosteroid. It acts as a positive allosteric modulator
Indication and administration: Zulresso is indicated for moderate to severe postpartum depression in adults within four
Efficacy and safety: In clinical trials, brexanolone produced a statistically significant improvement in depressive symptoms versus
Regulatory status: FDA approved Zulresso in 2019 for the treatment of postpartum depression. Its use requires